🖼
Fig. 4. — MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers.
active
paper figure
Created: 2026-04-21T18:29:40
By: paper_figures_tool
Quality:
50%
🔗 External
ID: paper-fig-paper-5fa244f809e0-4
Fig. 4.Figure 4
Reconstitution of miR223-3p induces synthetic lethality in HR-deficient cancers. ( A ) QRT-PCR comparing the levels of miR223-3p and miR223-5p in Jurkat cells (HR-replete), MDA-MB-436 (BRCA1-mutant breast cancer cell line), and UWB1.289 (BRCA1-mutant ovarian cancer cell line). ( B ) QRT-PCR showing the expression of miR223-3p following transfection with miR223-3p in MDA-MB-436 breast cancer cells. ( C ) Clonogenic survival assay showing the number of colonies in MDA-MB-435, UWB1.289, and MCF7 (HR-replete breast cancer) cells upon transfection of miR223-3p. ( D ) Clonogenic survival assay in MDA-MB-436 after depletion of PARP1, CtIP, and PSO4. ( E ) Comparison of number of colonies in MDA-MB-436, and HCC-1937 (BRCA1-mutant breast cancer) cells in the presence of olaparib. ( F ) Clonogenic survival assay in HCC1937 cells after miR223-3p transfection.
▸Metadata
| pmid | paper-5fa244f809e0 |
| caption | Reconstitution of miR223-3p induces synthetic lethality in HR-deficient cancers. ( A ) QRT-PCR comparing the levels of miR223-3p and miR223-5p in Jurkat cells (HR-replete), MDA-MB-436 (BRCA1-mutant br |
| image_url | https://www.ebi.ac.uk/europepmc/articles/PMC6717293/bin/pnas.1903150116fig04.jpg |
| paper_title | MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers. |
| figure_label | Fig. 4. |
| figure_number | 4 |
| _schema_version | 1 |
| source_strategy | pmc_api |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.